Compounds > 2-hydroxy benzimidazole
Page last updated: 2024-12-05

2-hydroxy benzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Hydroxy benzimidazole is a heterocyclic compound with potential biological activity. It is a white solid with a melting point of 201-203°C. The compound can be synthesized via various methods, including the reaction of o-phenylenediamine with formic acid or the condensation of o-aminophenol with formamide. 2-Hydroxy benzimidazole exhibits a range of biological activities, including antibacterial, antifungal, and anti-inflammatory properties. It is being investigated for its potential therapeutic applications in the treatment of infectious diseases and inflammatory conditions. Furthermore, it serves as a building block for the synthesis of various other bioactive compounds. The compound is also studied for its potential applications in materials science, as it can form complexes with metal ions and act as a ligand in coordination chemistry.'

2-hydroxy benzimidazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11985
CHEMBL ID2152713
SCHEMBL ID37951
MeSH IDM0509868

Synonyms (95)

Synonym
HMS1783E17
ec 210-412-4
cv8118uzew ,
unii-cv8118uzew
BB 0242764
nsc178108
nsc-178108
2h-benzimidazol-2-one, 1,3-dihydro-
1,3-dihydro-2h-benzimidazol-2-one
AF-834/25000580
nsc 10383
urea, n,n'-(1,2-phenylene)-
2h-benzimidazol
nsc 178108
2(3h)-oxobenzimidazole
n,n'-(1,2-phenyleneurea)
ai3-60092
einecs 210-412-4
2-benzimidazolol
2-hydroxybenzimidazole
urea,n'-(1,2-phenylene)-
wln: t56 bnvnj
615-16-7
2-oxobenzimidazole
benzamidazole-2(3h)-one
2-benzimidazolone
2-.alpha.-hydroxybenzimidazole
nsc10383
n,2-phenyleneurea)
o-phenyleneurea
nsc-10383
2-benzimidazolinone
1,3-dihydrobenzimidazol-2-one
2(3h)-benzimidazolone
2-hydroxybenzimidazole, 97%
STK056075
AKOS000269651
silnnfmwimzveq-uhfffaoysa-
H0739
1,3-dihydro-benzoimidazol-2-one
AKOS015920049
1h-1,3-benzodiazol-2-ol
CHEMBL2152713 ,
bdbm50393071
2,3-dihydro-2-oxo-1h-benzimidazole
2-hydroxy-benzimidazol
2(1h)-benzimidazolone
102976-62-5
FT-0612581
2,3-dihydro-1h-1,3-benzodiazol-2-one
PS-5766
GF-0113
1,3-dihydro-2h-benzo[d]imidazol-2-one
F0728-0008
1h-benzo(d)imidazol-2-ol
lansoprazole impurity d
benzimidazolol [usp impurity]
lansoprazole impurity d [ep impurity]
rabeprazole sodium impurity k [ep impurity]
1,3-dihydro-2h-benzimidazole-2-one
STL360330
1h-benzimidazol-2-ol
SCHEMBL37951
1h-benzimidazol-2-one
benzimidazolinone
1h-benzo[d]imidazol-2(3h)-one
benzimidazol-2(3h)-one
2-hydroxybenzoimidazole
(3h)-benzimidazolone
2-hydroxy-1h-benzimidazole
2-hydroxy benzimidazole
1,3-dihydrobenzoimidazol-2-one
2,3-dihydrobenzimidazol-2-one
2,3-dihydro-1h-benzimidazole-2-one
benzimidazolin-2-one
azaoxindole
DTXSID0060642
lansoprazole ep impurity d
Q-101098
mfcd00127894
CS-W008003
Z56924489
1h-benzimidazol-2-ol(9ci)
SY033248
hydroxybenzimidazole
FT-0717793
BCP18291
o-phenylene urea
1h-benzo[d]imidazol-2-ol
Q818479
EN300-17387
F12393
STARBLD0016990
HY-W008003
PD065534
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D-amino-acid oxidaseHomo sapiens (human)IC50 (µMol)100.00000.00401.119910.0000AID692851
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
proline catabolic processD-amino-acid oxidaseHomo sapiens (human)
digestionD-amino-acid oxidaseHomo sapiens (human)
D-amino acid catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine catabolic processD-amino-acid oxidaseHomo sapiens (human)
dopamine biosynthetic processD-amino-acid oxidaseHomo sapiens (human)
D-alanine catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine metabolic processD-amino-acid oxidaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumD-amino-acid oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
D-amino-acid oxidase activityD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-amino-acid oxidaseHomo sapiens (human)
identical protein bindingD-amino-acid oxidaseHomo sapiens (human)
FAD bindingD-amino-acid oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
mitochondrial outer membraneD-amino-acid oxidaseHomo sapiens (human)
extracellular regionD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomal matrixD-amino-acid oxidaseHomo sapiens (human)
cytosolD-amino-acid oxidaseHomo sapiens (human)
cell projectionD-amino-acid oxidaseHomo sapiens (human)
presynaptic active zoneD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
AID1389532Inhibition of DAAO (unknown origin) at 20 uM2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors.
AID692851Inhibition of human recombinant DAAO expressed in HEK293 cells using D-serine as substrate after 20 mins by horseradish peroxidase-coupled assay2012ACS medicinal chemistry letters, Oct-11, Volume: 3, Issue:10
Synthesis and SAR of 1-hydroxy-1H-benzo[d]imidazol-2(3H)-ones as Inhibitors of D-Amino Acid Oxidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.96 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
catechol
[no description available]		2.4110catecholsallelochemical;
genotoxin;
plant metabolite
guaiacol
Guaiacol: An agent thought to have disinfectant properties and used as an expectorant. (From Martindale, The Extra Pharmacopoeia, 30th ed, p747). methylcatechol : Any member of the class of catechols carrying one or more methyl substituents.. guaiacol : A monomethoxybenzene that consists of phenol with a methoxy substituent at the ortho position.		2.4110guaiacolsdisinfectant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
expectorant;
plant metabolite
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		2.4110imidazole
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		2.4110monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
acetohydroxamic acid
acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.		2.4110acetohydroxamic acids;
carbohydroximic acid		algal metabolite;
EC 3.5.1.5 (urease) inhibitor
deferiprone
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.		2.41104-pyridonesiron chelator;
protective agent
gaboxadol
gaboxadol: GABA agonist; inhibitor of GABA uptake systems; structure		2.1710oxazole
benzimidazole
1H-benzimidazole : The 1H-tautomer of benzimidazole.		7.0310benzimidazole;
polycyclic heteroarene
benzoxazolone
benzoxazolone: RN given refers to parent cpd; structure. 2-benzoxazolinone : A member of the class of benzoxazoles that is 2,3-dihydro-1,3-benzoxazole carrying an oxo group at position 2.		2.1710benzoxazoleallelochemical;
phytoalexin
3-hydroxy-2-oxoindole
3-hydroxyindolin-2-one: structure in first source. 3-hydroxyindolin-2-one : An oxindole that is 1,3-dihydro-2H-indol-2-one substituted by a hydroxy group at position 3.		2.0710hydroxyindoles;
oxindoles
barbituric acid
barbituric acid: RN given refers to parent cpd; structure from Merck Index, 9th ed, #966. barbituric acid : A barbiturate, the structure of which is that of perhydropyrimidine substituted at C-2, -4 and -6 by oxo groups. Barbituric acid is the parent compound of barbiturate drugs, although it is not itself pharmacologically active.		2.4110barbituratesallergen;
xenobiotic
4-toluenesulfonamide
4-toluenesulfonamide: RN given refers to parent cpd. toluene-4-sulfonamide : A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4.		2.4110sulfonamide
isatin
tribulin: endogenous MONOAMINE OXIDASE inhibitory activity extractable into ethyl acetate found in brain and many mammalian tissues and fluids; ISATIN is a major component; produced in excess following alcohol withdrawal;		2.1710indoledioneEC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
benzenesulfonamide
[no description available]		2.4110sulfonamide
2-aminobenzothiazole
[no description available]		2.1710benzothiazoles
hydantoins
Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.		2.4110imidazolidine-2,4-dione
lysidine
lysidine: structure in first source; do not confuse with the imidazole-derivative known as lysidine. lysidine : Cytidine in which the 2-keto group on the cytosine ring is substituted by an epsilon-Llysyl residue.		2.4110
8-aminoquinoline
[no description available]		2.4110
1,2-Dihydroquinolin-2-imine
[no description available]		2.4110aminoquinoline
4-methylimidazole
4-methylimidazole: RN given refers to parent cpd. 4-methylimidazole : Imidazole substituted at position 4 by a methyl group.		2.4110imidazolescarcinogenic agent;
reaction intermediate
2-hydroxybenzothiazole
2-hydroxybenzothiazole : Benzothiazole substituted with a hydroxy group at the 2-position.		2.4110benzothiazole
pyromeconic acid
pyromeconic acid: from herb Dengzhanhua; structure		2.4110
serinol
serinol: RN given refers to cpd without isomeric designation		2.4110
1-hydroxy-2(1h)-pyridinone
1-hydroxy-2(1H)-pyridinone: structure in first source		2.4110
8-hydroxy-2-quinolinecarboxylic acid
[no description available]		2.4110quinolines
1-phenylimidazole
1-phenylimidazole: ligand for cytochrome P-450 & inhibitor of microsomal oxidation		2.4110
3-indazolinone
3-indazolinone: structure given in first source		2.1710
5-Chloro-1H-indole-2,3-dione
[no description available]		2.1710indolesanticoronaviral agent
1-methyl-3-hydroxypyridine-2-one
[no description available]		2.4110
2-acetylcyclopentanone
2-acetylcyclopentanone: an enolate-forming compound that is protective against electrophilic drugs; structure in first source		2.4110
8-(methylsulfonylamino)quinoline
8-(methylsulfonylamino)quinoline: has diabetogenic properties; structure given in first source		2.4110
hydroxyl radical
Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.		2.0310oxygen hydride;
oxygen radical;
reactive oxygen species
5-Fluoroisatin
[no description available]		2.1710indolesanticoronaviral agent
2-mercaptobenzimidazole
2-mercaptobenzimidazole: purine synthesis antimetabolite; RN given refers to parent cpd		2.6620
3-hydroxyquinolin-2(1h)-one
3-hydroxyquinolin-2(1H)-one: structure in first source. dihydroxyquinoline : Any hydroxyquinoline in which the number of hydroxy substituents is specified as two.		2.1710hydroxyquinoline;
quinolone
thiohydantoins
Thiohydantoins: Sulfur analogs of hydantoins with one or both carbonyl groups replaced by thiocarbonyl groups.		2.4110
6-Chlorobenzo[d]isoxazol-3-ol
[no description available]		2.1710benzisoxazole
4-hydroxyquinazoline
4-oxo-3,4-dihydroquinazoline: structure in first source		2.0310quinazolines
4,5-dihydro-1h-1,2,4-triazol-5-one
4,5-dihydro-1H-1,2,4-triazol-5-one: a 1,2,4-triazole derivative; structure given in first source		2.4110
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610